What is claimed is:

1. A composition of matter comprising the structure

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

wherein:

F^1 is a vehicle;

X^1 and X^2 are each independently selected from $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

P^1, P^2, P^3, and P^4 are each independently selected from SEQ ID NOS: 45 and 46;

L^1, L^2, L^3, and L^4 are each independently linkers; and

a and b are each independently 0 or 1, provided that at least one of a and b is 1;

c, d, e, and f are each independently 0 or 1, provided that if P^1 is SEQ ID NO: 45 and P^2 is SEQ ID NO: 46, then d is 1;

and wherein said composition of matter does not comprise SEQ ID NO: 43.

2. The composition of matter of Claim 1 of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

3. The composition of matter of Claim 1 of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2.$$

4. The composition of matter of Claim 1 wherein F^1 is an Fc-region.
5. The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.
6. The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.
7. The polypeptide of Claim 1, wherein F^1 is a water-soluble polymer or a carbohydrate.
8. The protein of Claim 7, wherein the polymer is polyethylene glycol.

9. The protein of Claim 7, wherein the carbohydrate is dextran.

10. A polypeptide of Claim 1 capable of eliciting B cell growth, survival, or activation in mesenteric lymph nodes.

11. An isolated nucleic acid encoding a polypeptide of Claim 1.

12. The nucleic acid of Claim 11 including one or more codons preferred for Escherichia coli expression.

13. The nucleic acid of Claim 11 having a detectable label attached thereto.

14. An expression vector comprising the nucleic acid of Claim 11.

15. A host cell comprising the expression vector of Claim 14.

16. The host cell of Claim 15, wherein the cell is a prokaryotic cell.

17. The host cell of Claim 16, wherein the cell is Escherichia coli.

18. A pharmaceutical composition comprising a therapeutically effective amount of a protein of Claim 1 in a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer and/or anti-oxidant.

19. A method of modulating AGP-3-related activity in a mammal, which comprises administering a therapeutically effective amount of the composition of matter of Claim 1.

20. The method of Claim 22, wherein the AGP-3-related activity takes place in mesenteric lymph nodes.

21. A polypeptide comprising an antibody sequence in which one or more amino acids from antibody variable domains or CDR regions are replaced by sequences selected from SEQ ID NOS: 45 and 46.

22. The polypeptide of Claim 21, wherein a first CDR region is replaced by SEQ ID NO: 45 and a second CDR region is replaced by SEQ ID NO: 46.

23. The polypeptide of Claim 21, wherein all CDR regions are replaced by SEQ ID NO: 45.

24. An isolated nucleic acid encoding a polypeptide of Claim 21.

25. The nucleic acid of Claim 24 having a detectable label attached thereto.

26. An expression vector comprising the nucleic acid of Claim 24.

27. A host cell comprising the expression vector of Claim 26.

28. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide of Claim 21 in a pharmaceutically acceptable carrier, adjuvant, solubilizer, stabilizer and/or anti-oxidant.

29. A method of modulating AGP-3-related activity in a mammal, which comprises administering a therapeutically effective amount of the composition of matter of Claim 21.

30. The method of Claim 29, wherein the AGP-3-related activity takes place in mesenteric lymph nodes.